Amgen Inc. (NASDAQ:AMGN) Shares Bought by Robeco Institutional Asset Management B.V.

Robeco Institutional Asset Management B.V. boosted its holdings in Amgen Inc. (NASDAQ:AMGN - Free Report) by 10.4% during the first quarter, according to its most recent Form 13F filing with the SEC. The fund owned 462,905 shares of the medical research company's stock after acquiring an additional 43,727 shares during the period. Robeco Institutional Asset Management B.V. owned 0.09% of Amgen worth $144,218,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in the business. First Pacific Financial raised its position in Amgen by 304.5% in the first quarter. First Pacific Financial now owns 89 shares of the medical research company's stock valued at $28,000 after purchasing an additional 67 shares during the period. Pinney & Scofield Inc. purchased a new stake in Amgen in the fourth quarter valued at approximately $26,000. Ritter Daniher Financial Advisory LLC DE raised its position in Amgen by 66.2% in the fourth quarter. Ritter Daniher Financial Advisory LLC DE now owns 128 shares of the medical research company's stock valued at $33,000 after purchasing an additional 51 shares during the period. Synergy Investment Management LLC purchased a new stake in Amgen in the fourth quarter valued at approximately $34,000. Finally, Atala Financial Inc purchased a new stake in Amgen in the fourth quarter valued at approximately $34,000. 76.50% of the stock is currently owned by institutional investors and hedge funds.

Amgen Stock Down 0.7%

Shares of AMGN stock traded down $1.98 on Friday, reaching $277.13. 2,894,198 shares of the stock were exchanged, compared to its average volume of 2,833,059. The company has a current ratio of 1.17, a quick ratio of 0.88 and a debt-to-equity ratio of 8.70. The business's 50 day moving average price is $281.02 and its 200 day moving average price is $286.01. The company has a market capitalization of $149.02 billion, a price-to-earnings ratio of 25.29, a PEG ratio of 2.52 and a beta of 0.51. Amgen Inc. has a twelve month low of $253.30 and a twelve month high of $346.85.

Amgen (NASDAQ:AMGN - Get Free Report) last issued its earnings results on Thursday, May 1st. The medical research company reported $4.90 EPS for the quarter, topping analysts' consensus estimates of $4.18 by $0.72. The firm had revenue of $8.15 billion during the quarter, compared to the consensus estimate of $8.05 billion. Amgen had a net margin of 17.39% and a return on equity of 176.11%. The company's revenue was up 9.4% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $3.96 earnings per share. As a group, sell-side analysts expect that Amgen Inc. will post 20.62 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, SVP Rachna Khosla sold 1,500 shares of the business's stock in a transaction on Thursday, June 5th. The shares were sold at an average price of $289.68, for a total transaction of $434,520.00. Following the completion of the transaction, the senior vice president now owns 8,162 shares in the company, valued at approximately $2,364,368.16. The trade was a 15.52% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders own 0.76% of the company's stock.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on AMGN. Bank of America boosted their target price on Amgen from $275.00 to $294.00 and gave the company an "underperform" rating in a research report on Wednesday, March 5th. Guggenheim began coverage on Amgen in a research report on Tuesday, May 20th. They issued a "neutral" rating and a $288.00 target price on the stock. Erste Group Bank lowered Amgen from a "strong-buy" rating to a "hold" rating in a research report on Thursday, May 8th. Wall Street Zen raised Amgen from a "buy" rating to a "strong-buy" rating in a research report on Sunday, May 18th. Finally, UBS Group reissued a "neutral" rating and issued a $315.00 target price (down previously from $319.00) on shares of Amgen in a research report on Friday, May 2nd. Two investment analysts have rated the stock with a sell rating, twelve have issued a hold rating, nine have assigned a buy rating and two have assigned a strong buy rating to the company's stock. According to MarketBeat.com, Amgen has an average rating of "Hold" and a consensus target price of $309.22.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.